Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
-Conference Call and Webcast Today,
Company Highlights and 2018 Milestones
- Completed stock purchase transaction between Daré
Bioscience, Inc.(formerly known as Cerulean Pharma Inc.) and Daré Bioscience Operations, Inc.in July 2017.
- Entered into a worldwide license and development agreement for a clinical Phase 2b stage asset, Topical Sildenafil, for the treatment of Female Sexual Arousal Disorder in
- The Company intends to communicate with the
U.S. Food and Drug Administrationin mid-2018 regarding the Phase 2b study of Topical Sildenafil.
- Pending these discussions, the Company anticipates commencing a Phase 2b study of Topical Sildenafil in the fourth quarter of 2018.
- The Company intends to communicate with the
- Entered into a worldwide development and option agreement for novel injectable formulations of etonogestrel seeking to provide contraceptive protection for periods of six and 12 months in
- The Company expects to commence enrollment in the OvapreneTM postcoital test clinical trial in the second quarter of 2018.
“2017 was a year of transformative growth for Daré Bioscience as we established a strong foundation for our goal of building a preeminent company in women’s reproductive health. We expect that our year end cash balance of approximately
Full Year 2017 Financial Summary
General and administrative expenses for the full year ended
Research and development expenses for the full year ended
The Company incurred a non-cash impairment charge of
The net loss for the full year ended
Conference Call and Webcast
Daré Bioscience will host a live conference call and webcast 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss Daré’s financial results and provide a general business update.
The live webcast and a replay may be accessed by visiting the investor relations section of Daré’s website at http://www.darebioscience.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
Alternatively, please call (844) 831-3031 (U.S.) or (443) 637-1284 (international) to listen to the live conference call. The conference ID number for the live call is 7696698. Please dial in approximately 10 minutes prior to the call.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health that address clear therapeutic gaps. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel and differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré currently has two product candidates in clinical development. The first is Ovaprene™, a non-hormonal monthly contraceptive ring intended to provide protection over multiple weeks between menses. The second is SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder. SST-6007 incorporates sildenafil, the same active ingredient in Viagra®, in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. Daré also has an option to enter into a license agreement for ORB-204 and ORB-214, preclinical stage injectable etonogestrel contraceptives with target 6- and 12-month durations.
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's ability to develop Ovaprene and Topical Sildenafil at the cost and in accordance with the targeted timelines and milestones set forth herein, expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Daré's products and the qualifications and expertise of Daré's management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré's owned and licensed intellectual property rights, and other factors discussed in the "Risk Factors" section of Daré's Report on Form 10-K filed with the
Investors on behalf of Daré
Media on behalf of Daré
Source: Daré Bioscience
Source: Dare Bioscience, Inc.